BRIDGEWATER, N.J., Oct. 21, 2019 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TXS: BHC), today announced the U.S. launch of PreserVision® AREDS 2 Formula minigel eye vitamins. The new minigels will replace the currently offered PreserVision AREDS 2 Formula soft gels, offering patients an easier-to-swallow option compared to the original AREDS 2 soft gels. PreserVision® AREDS 2 Formula minigel eye vitamins contain the exact nutrient formula recommended by the National Eye Institute (NEI) for people with moderate to advanced Age-related Macular Degeneration (AMD) following the landmark AREDS2 clinical study.

"AMD is a leading cause of vision loss in Americans age 50 and older. For my patients who are diagnosed with moderate to advanced AMD, I typically recommend a plan that includes regular exercise, a healthy diet, and PreserVision – a supplement that contains nutrients recommended by the National Eye Institute to help reduce the risk of AMD progression in these patients," said Rishi Singh, M.D., Cole Eye Institute, Cleveland Clinic. "I am pleased to recommend this new option to my patients who have inquired about the availability of a smaller sized PreserVision AREDS 2 formula vitamin."¹

About Bausch + Lomb
Bausch + Lomb, a Bausch Health Companies Inc. company, is a leading global eye health organization that is solely focused on helping people see. Its core businesses include over-the-counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in more than 100 countries. For more information, visit www.bausch.com.

About Bausch Health
Bausch Health Companies Inc. (TSX:BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com.

Forward-looking Statements
This news release may contain forward-looking statements which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Bausch Health's most recent annual or quarterly report and detailed from time to time in Bausch Health's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.                                 

PreserVision is a trademark of Bausch & Lomb Incorporated or its affiliates.
AREDS2 is a registered trademark of the United States Department of Health and Human Services (HHS).
© 2019 Bausch & Lomb Incorporated or its affiliates.
PVN.0093.USA.19